

Clinical trials of rimonabant 5mg

TrialResults-center www.trialresultscenter.org

1 cardiovascular prevention

Trial	Treatments	Patients	Trials design and methods
rimonabant 5mg vs placebo			
RIO europe 5mg , 2005 n=603/305 follow-up: 1 y	5 mg rimonabant versus placebo	patients with body-mass index 30 kg/m2 or greater, or body-mass index greater than 27 kg/m2 with treated or untreated dyslipidaemia, hypertension, or both	Parallel groups double-blind

More details and results :

- weight-loss drugs for cardiovascular prevention in overweight or obese patients at <http://www.trialresultscenter.org/go-Q444>

References

RIO europe 5mg, 2005:

Van Gaal LF, Rissanen AM, Scheen AJ, Ziegler O, Rossner S Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study. Lancet 2005 Apr 16-22;365:1389-97 [[15836887](#)]

Entry terms: rimonabant, rimonabant, SR141716, SR 141716, Acomplia, Zimulti, Sanofi-Synthelabo brand of rimonabant, SR 141716A, SR141716A, SR-141716A,